Pharma BD Deal Intelligence

Monopar Therapeutics Inc. / NorthStar Medical Radioisotopes, LLC

2024 · Licensing/Option · Complete

Monopar and NorthStar amended and extended their collaboration, entering a long-term non-exclusive master supply agreement for NorthStar to supply actinium-225 to Monopar. The amendment clarified economic terms and jointly developed IP rights, with Monopar acquiring NorthStar's rights so that Monopar holds full ownership and title to its MNPR-101 radiopharmaceutical platform; both parties share ownership of a filed patent application on PCTA as an Ac-225 linker. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals